{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-069338","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.336264+00:00","generated_at":"2026-05-31T08:57:53.533774+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ABVC BioPharma Q2 2024 EPS improves 86.8% to -$0.09; licensing deals worth up to $292M","bullets":["EPS improved 86.8% YoY to -$0.09 in Q2 2024 from -$0.68; revenue surged to $117,142 from $6,109.","Executed global licensing agreements for Vitargus (up to $187M) and oncology products (up to $105M) totaling potential $292M.","Received $116,000 cash milestone in June 2024 from Vitargus licensing.","Shareholders' equity stood at $7.8M as of June 30, 2024.","Obtained US, Taiwanese, and Australian patents for Polygala extract for MDD and ADHD; FDA approved four INDs for oncology."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-069338","json":"https://secwatch.observer/filing/0001213900-24-069338.json","markdown":"https://secwatch.observer/filing/0001213900-24-069338.md","text":"https://secwatch.observer/filing/0001213900-24-069338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024069338/0001213900-24-069338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024069338/ea0211475-8k_abvc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:57:53.533774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}